Merck & Co has reported new data with its oral antiviral molnupiravir that suggests it is not as effective against COVID-19 as originally hoped. An updated readout from the MOVE-OUT study of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback